Celularity Inc (CELU) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Celularity Inc (CELU) has a cash flow conversion efficiency ratio of 0.207x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.16 Million) by net assets ($-20.09 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Celularity Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Celularity Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read CELU current and long-term liabilities for a breakdown of total debt and financial obligations.
Celularity Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Celularity Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hunyvers SA
PA:ALHUN
|
0.173x |
|
Lisata Therapeutics Inc.
NASDAQ:LSTA
|
-0.195x |
|
YoungWoo DSP Co.Ltd
KQ:143540
|
0.118x |
|
Briacell Therapeutics Corp
NASDAQ:BCTX
|
-1.143x |
|
Q-Gold Resources Ltd
V:QGR
|
0.112x |
|
Silla Textile Co.Ltd
KQ:001000
|
0.014x |
|
Petratherm Ltd
AU:PTR
|
-0.044x |
|
Fortune Bay Corp
V:FOR
|
-0.022x |
Annual Cash Flow Conversion Efficiency for Celularity Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Celularity Inc from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see CELU market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $8.84 Million | $-6.40 Million | -0.724x | +23.31% |
| 2023-12-31 | $40.96 Million | $-38.69 Million | -0.944x | -36.25% |
| 2022-12-31 | $198.90 Million | $-137.88 Million | -0.693x | +37.40% |
| 2021-12-31 | $99.42 Million | $-110.10 Million | -1.107x | +67.21% |
| 2020-12-31 | $18.71 Million | $-63.19 Million | -3.377x | -42306.64% |
| 2019-12-31 | $137.86 Million | $-1.10 Million | -0.008x | -284.56% |
| 2018-12-31 | $-125.85K | $-543.00 | 0.004x | -- |
About Celularity Inc
Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioB… Read more